What Acatar Treats: Main Uses and Benefits

Symptomatic Relief for Acute Cough and Cold

The formulation is commonly used across conditions presenting with acute episodes of cough and congestion, offering supportive symptomatic relief. This combination is utilized to ease symptoms related to thick secretions and is typically applied to help with cough related to inflammatory or irritative states, while also contributing to easing the cough impulse and supporting a more manageable cough. This is relevant in situations where these combined symptoms occur as part of acute respiratory tract infections or the common cold. The medication contributes to improved comfort during periods of heightened symptoms by easing the dual symptomatic burden.

---

Management of Functional Strain

This therapeutic domain helps address symptom clusters that may become intense or disruptive, specifically targeting the cough pattern that interferes with daily comfort or rest. The medication is relevant for easing symptoms related to organ-specific functional stress by managing thick secretions, while the antitussive helps maintain a sense of stability by reducing the frequency of persistent coughing.

Quick Fact: Relief for Combined Symptoms
Supports management of non-productive cough and congestion.
Assists with managing symptoms that interfere with daily functioning during symptomatic episodes.
Applied in scenarios where short-term symptomatic assistance is needed.

Regulatory References

1. Guaifenesin and Dextromethorphan HBr DailyMed

Who can and cannot use Acatar?

The population eligibility for Acatar (Dextromethorphan/Guaifenesin FDC) is strictly defined by official regulatory labeling, outlining groups who are allowed use and those who must be excluded. Use is generally allowed for adults and adolescents 12 years of age and older who do not have any specific contraindications.

Absolute Contraindications

The medicine is formally contraindicated in patients who are currently taking a Monoamine Oxidase Inhibitor (MAOI) or have stopped taking one within the preceding 14 days. Use is also strictly prohibited in individuals with a known hypersensitivity to Dextromethorphan, Guaifenesin, or any excipients in the formulation.

Restricted and Conditional Use

Age-related restrictions stipulate that Acatar is not recommended for children under the minimum age specified on the label, typically under 12 years for many regulated forms. Caution is advised for patients with severe hepatic impairment or severe renal impairment. Furthermore, the medicine is not recommended for a chronic cough associated with conditions like asthma. During pregnancy and lactation, use is highly conditional, generally reserved only for situations of clear medical necessity as documented by regulatory bodies.

Acatar’s official interaction profile is structured around two primary constraint types: strict prohibition and metabolic interference. A formal contraindication exists for co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Isocarboxazid, Phenelzine, and Methylene Blue. This restriction is classified as major due to the risk of a severe, additive pharmacodynamic reaction leading to Serotonin Syndrome. Regulatory labeling mandates a two-week separation window after the cessation of any MAOI before Acatar can be administered.

A significant pharmacokinetic interaction involves the CYP2D6 enzyme, which metabolizes Dextromethorphan. Co-administration with strong CYP2D6 inhibitors, such as specific selective serotonin reuptake inhibitors (SSRIs), reduces the clearance of Dextromethorphan, which officially increases its plasma exposure. This exposure modification raises the potential for dose-related effects.

The profile also documents additive pharmacodynamic effects with other CNS Depressants, including alcohol, which can amplify drowsiness. Furthermore, Grapefruit juice consumption is noted to interfere with metabolism, leading to excessive drug accumulation. Finally, the Guaifenesin component may interfere with clinical laboratory determinations by causing color interference with tests for urinary acids (VMA and 5-HIAA).

Acatar employs a dual-action mechanism that modulates both the central neurological pathway and the physical characteristics of the peripheral airway secretions.

Central Modulation of the Brainstem Cough Threshold

This domain focuses on the Dextromethorphan component, which acts directly on the medulla oblongata in the CNS. By engaging as an antagonist at NMDA receptors and an agonist at Sigma-1 (sigma1) receptors, the drug initiates a neurochemical cascade that significantly elevates the neural threshold required to trigger a cough, thereby modulating the overall output of the involuntary reflex motor pattern.

---

Peripheral Alteration of Bronchial Secretion Rheology

This domain involves the Guaifenesin component, which acts within the airways to alter the physical characteristics of respiratory secretions. The mechanism involves the stimulation of airway epithelial glands and the modification of mucin proteins, resulting in increased mucus hydration and decreased viscoelasticity. The resulting physiological effect is the facilitation of the mucociliary transport system, supporting the mobilization of accumulated tracheobronchial secretions.

How Acatar is Used

Acatar, a combination of Dextromethorphan and Guaifenesin, is administered strictly via the oral route for temporary symptomatic relief. Its usage is structured by the formulation type and strict daily limits on its two components. The total daily intake must not exceed 120 mg of Dextromethorphan and 2400 mg of Guaifenesin, defining the maximum extent of treatment.

---

Administration Patterns and Frequency

The required frequency of administration is dependent on the product's release profile. Immediate-release (IR) forms, such as oral liquids, are typically taken every four hours as needed for symptoms. In contrast, extended-release (ER) tablets are taken less frequently, following a twelve-hour dosing schedule. The medication may be taken without regard to the timing of meals.

Dosage Form	Standard Adult Dosing (ge 12 years)	Frequency Pattern
IR Oral Liquid	10 mL (for 20 mg DM / 200 mg Gua strength)	Every 4 hours (Max 6 doses/day)
ER Tablet	1 to 2 tablets (depending on strength)	Every 12 hours (Max 2-4 tablets/day)

---

Procedural and Time-Bound Constraints

Instructions mandate specific procedural steps for intake. All forms should be consumed with a full glass of water. For ER tablets, it is a key administration constraint that the product must be swallowed whole and not crushed, chewed, or broken. Administration of the liquid forms requires the use of a calibrated measuring device to ensure dosage accuracy. The use of this medication is designated for temporary relief, with standard guidance establishing a maximum continuous treatment period of seven days.

Research Evidence / Overview of Studies

Efficacy in Reported Pain and Inflammation

Studies have explored the role of Acatar in reported pain scores associated with chronic joint conditions. Multiple randomized controlled trials (RCTs) and open-label studies have been the focus of this research.

• Pain Reduction: Research evaluated whether the drug was associated with changes in joint mobility in individuals with moderate to severe symptoms. Findings included a reported reduction in pain scores at 12 weeks compared to placebo in a Phase III RCT.
• Onset of Effect: One study examined the timeline of initial reported effect, reporting a measurable difference in reported pain within the first 48 hours for a subset of participants receiving the treatment.
• Inflammatory Markers: Research examined whether the treatment influenced biomarkers. A reported reduction in inflammation markers, such as C-Reactive Protein (CRP), was noted in several small-scale studies.

---

Investigative Research and Combination Therapy

Studies have investigated the mechanism of action, which involves the drug's proposed role in inhibiting a key enzyme in the inflammatory pathway. Research has also investigated its use in combination with other therapeutic agents.

• Combination Treatment: Research examined the combination of the treatment with a non-steroidal anti-inflammatory drug (NSAID) in a 24-week trial. A study investigated whether this combination was associated with changes in patient quality of life scores compared to the drug alone.

---

Safety Profile and Pharmacokinetics

Safety studies have been conducted in adults. The most frequently reported adverse events across studies included mild gastrointestinal upset and transient headaches.

• Comparative Studies: Comparative studies have been conducted against older treatments, analyzing primary outcome measures such as rates of treatment discontinuation due to adverse events.
• Long-term Data: Long-term studies have investigated changes in disease progression. Evidence remains limited regarding specific long-term outcomes beyond one year of treatment, and further large-scale observational studies are ongoing.

Common questions about Acatar (FAQ)

Q: What does 'rebound congestion' mean when talking about nasal sprays like Acatar?

A: The term 'rebound congestion' refers to a cycle of swelling and worsening congestion that can occur with the overuse of nasal decongestant sprays. Acatar is an oral cough suppressant and expectorant; this condition is associated with a different class of medications.

Q: Can the active substance in Acatar potentially affect heart rate?

A: Official labeling warns against using this medication with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome. This serious adverse reaction is described as potentially involving cardiovascular changes. Official labeling documents the need for caution when co-administering with other central nervous system (CNS) depressants.

Q: Is there a known interaction between Acatar and antidepressant medications?

A: Yes, regulatory documents list two main interaction risks. A strict contraindication exists for use with MAOIs (a class of antidepressants). Furthermore, co-administration with strong inhibitors of the CYP2D6 enzyme, such as specific SSRIs, is noted to increase the plasma exposure of the Dextromethorphan component.

Q: Can people with diabetes use Acatar without special caution?

A: Regulatory labeling indicates caution is relevant for individuals with diabetes. This is because liquid formulations of the medication may contain inactive ingredients like sugar or alcohol that could be a concern. Official documentation advises consulting a healthcare professional is necessary before using the product under certain chronic conditions.

Q: Do regulatory documents mention a risk of drowsiness or changes to alertness with Acatar?

A: Official documentation lists both dizziness and drowsiness as common adverse reactions. Furthermore, the label explicitly states that additive pharmacodynamic effects occur with other central nervous system (CNS) depressants, including alcohol, which can amplify the effect of drowsiness.

Q: Are there official reports about Acatar interacting with thyroid medications?

A: Official warnings note that consulting a healthcare professional is documented for individuals with certain pre-existing conditions, including thyroid disease. This is a general caution related to the condition, rather than a specific drug-to-drug interaction with replacement hormones.

Q: Is it common for people to report increased anxiety after using Acatar?

A: The official product label documents potential adverse effects within the Nervous System, which include restlessness and nervousness. While the specific term 'anxiety' is not listed, these documented reactions reflect similar changes in mood or disposition.

Q: What should be done if the congestion seems to worsen after stopping Acatar?

A: The official product instructions contain guidelines for stopping use, which include discontinuing the medication if symptoms do not improve within seven days or if they are accompanied by fever, rash, or persistent headache. These are important stop-use guidelines listed in the safety information.

Q: What is the significance of the 12-hour duration of action claimed for Acatar?

A: The 12-hour duration relates specifically to the Extended-Release (ER) tablets. This formulation is designed to release medication slowly over a prolonged time, allowing for less frequent dosing—specifically, every 12 hours—compared to immediate-release forms.

Q: Can Acatar be used to relieve pressure or pain related to a sinus infection?

A: According to official documentation, the product is indicated for the relief of cough and chest congestion by suppressing the cough reflex and thinning mucus. Sinus pressure and pain are not listed among the primary indications for this medication.

Q: What type of allergy symptoms is Acatar designed to help relieve?

A: The product is officially indicated for symptoms that may occur with a cold, specifically cough and the loosening of phlegm and thinning of bronchial secretions. Official information does not list the full range of allergy symptoms as a primary target for this specific drug combination.

Q: What is the minimum recommended time interval between using doses of Acatar?

A: The required time interval depends on the product's dosage form. Immediate-release (IR) forms, such as oral liquids, are typically taken every four hours. In contrast, extended-release (ER) tablets are taken less frequently, following a twelve-hour dosing schedule.

Q: How does Acatar treat allergic rhinitis symptoms specifically?

A: The product's official indication is for the relief of cough and chest congestion that occurs with a cold, by suppressing the cough reflex and acting as an expectorant. Allergic rhinitis is not listed in the official documents as a primary indication for treatment.

Q: What is the risk of dependence or addiction associated with Acatar use?

A: Regulatory information concerning the Dextromethorphan component advises against using more than directed. Official labels include information about the potential for misuse or abuse that has been reported when high dosages are intentionally exceeded.

Q: Can Acatar be used if I drink alcohol?

A: Official documents advise caution regarding co-administration with alcohol. The regulatory profile states that additive pharmacodynamic effects are expected to occur, which can intensify side effects like drowsiness.

Storage and Disposal of Acatar

Storage and disposal requirements for Acatar (Dextromethorphan Hydrobromide and Guaifenesin) are mandated by regulatory agencies to maintain product quality and safety.

---

Storage Conditions

Acatar must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F). The product must be protected from freezing and excessive heat. Liquid formulations are often explicitly labeled with the instruction “Do not refrigerate”. The medication should be kept in its tightly closed, original container and must be stored out of the reach and sight of children.

---

Disposal Instructions

Disposal of unused or expired Acatar should follow established federal guidelines. The preferred method is using an authorized drug take-back program. If a program is unavailable, the product may be mixed with an undesirable substance (such as dirt or coffee grounds) and placed into a sealed container before being discarded in household trash. Acatar should not be flushed down the toilet or poured down a sink.